Price T Rowe Associates Inc Erasca, Inc. Call Options Transaction History
Price T Rowe Associates Inc
- $836 Billion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding ERAS
# of Institutions
143Shares Held
210MCall Options Held
3.1KPut Options Held
142K-
Frazier Life Sciences Management, L.P. Menlo Park, CA16.2MShares$48.5 Million2.26% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$48.5 Million4.2% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$41.2 Million1.36% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$39.7 Million0.0% of portfolio
-
Arch Venture Management, LLC Chicago, IL11.1MShares$33.1 Million15.29% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $365M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...